Citi initiated coverage of Becton Dickinson (BD) with a positive outlook, assigning a Buy rating and a $233 price target. This follows BD's decision to sell its Life Sciences Bioprocessing unit, a move that will streamline the company into a more focused medical technology entity. The sale, slated to close on February 9, 2026, is expected to reshape BD's strategy.

The divestiture will allow BD to concentrate on four core areas: Medical Essentials, Connected Care, Biopharma Systems, and Interventional, a market estimated at $70 billion growing at roughly 5% annually. Proceeds from the sale will strengthen BD's balance sheet, with roughly $4 billion earmarked for debt reduction, share buybacks, and continued R&D investments.

In the near term, investors should anticipate mixed financial reporting. Citi projects that fiscal first-quarter 2026 results results will still include the Life Sciences business. Operating margins are expected to remain flat year-over-year. Citi's price target is based on a 16-17 times multiple of estimated 2027 earnings.

Why does this matter? The Life Sciences sale is a strategic move, allowing BD to streamline operations and focus on its core med-tech competencies. This restructuring could lead to improved financial performance. Investors should watch for the company's execution of its plans and its ability to deliver consistent revenue growth.